Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.48 |
| ▸ | CTSS | P25774 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5235667 | 0.88 | ALDH1A1 (0.57) | GPR119EGLN2ALDH1A1MAPTLMNA | |
| SCHEMBL2471189 | 0.85 | MAPT (0.62) | GPR119EGLN2ALDH1A1MAPTLMNA | |
| SCHEMBL3486554 | 0.84 | GPR119 (0.73) | GPR119 | |
| SCHEMBL5211568 | 0.82 | GPR119 (0.74) | GPR119EGLN2ALDH1A1MAPTLMNA | |
| SCHEMBL24990167 | 0.82 | EGLN2 (0.63) | GPR119EGLN2CTSSCTSKALDH1A1 | |
| SCHEMBL22914841 | 0.81 | GPR119 (0.50) | GPR119EGLN2ALDH1A1MAPTLMNA | |
| SCHEMBL3861807 | 0.81 | HRH3 (0.62) | CTSSCTSKALDH1A1MAPTMEN1 | |
| SCHEMBL6182019 | 0.80 | GPR119 (0.60) | HPGDGPR119RECQLALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL3881766 | 0.80 | HRH3 (0.61) | CTSSCTSKALDH1A1MAPTMEN1 | |
| SCHEMBL3861953 | 0.79 | HRH3 (0.57) | CTSSCTSKALDH1A1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7592347-B2 | Piperazine derivates and their use for the treatment of neurological and psychiatric diseases | GLAXO GROUP LIMITED (GB) | 2009-09-22 | — | — | US | disclosed |
| EP-1615909-B1 | PIPERAZINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISEASES | GLAXO GROUP LTD (GB) | 2008-07-23 | — | — | EP | disclosed |
| US-20070054917-A1 | Piperazine derivates and their use for the treatment of neurological and psychiatric diseases | GLAXO GROUP LIMITED (GB) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054917-A1 | Piperazine derivates and their use for the treatment of neurological and psychiatric diseases | GRIN2A, GRIK5, GRIN2C | HPGD 1179/4885GPR119 1784/4885RECQL 3921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.